Hospital

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

Promoting weight management prior to pregnancy and in early life may yield stronger cardiovascular and maternal health.

Pharmacists should educate patients about their treatment regimen and potential adverse effects.

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.

These data provide compelling evidence to revise existing transfusion protocols, recommending 4F-PCC as the preferred treatment for hemostatic management in cardiac surgery.

This approval marks bevacizumab-nwgd as the sixth reference product to bevacizumab (Avastin).

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Amir Ali, PharmD, BCOP, and Allison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.

Automated diagnosis verification offers a promising alternative for managing the use of GLP-1 medications.

In patients with CKD, there were negative associations between the sodium cotransporter (NCC) and its phosphorylation (pNCC) in urinary extracellular vesicles (uEVs), but further research is needed to confirm these findings in a larger cohort.

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.

Pharmacists play a key role in educating patients and prescribers on the selection, use, and management of GLP-1 receptor agonists in diabetes care.

Matthew Lei, PharmD, BCOP, highlights the value of community, collaboration, and innovation at the HOPA Annual Conference.

Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.

Numerical differences were observed as early as Month 1.

Sophie Jabban discusses research presented at the SGO Annual Meeting highlighting significant disparities in MRI access for patients with cervical cancer receiving chemoradiation, with delays linked to both race and insurance status, underscoring systemic barriers that may impact timely treatment.

The approval was based on efficacy and safety data from a randomized, 3-arm, open-label phase 3 CHECKMATE-8HW trial.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.

Pharmacists are essential navigators in the complex landscape of gene therapy.

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Fatty acid metabolism plays a critical role in treatment responses.

Sophie Jabban discusses findings from 2 studies that highlight how geographic location, race, ethnicity, and social determinants of health contribute to delays in initiating chemoradiation for patients with cervical cancer.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, offers insights for oncology pharmacists treating patients with metastatic esophageal squamous cell carcinoma.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses a case study of a patient with metastatic esophageal squamous cell carcinoma.